Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases

@timoe2018 @BelliqueuseP @niklegame94 Et peu toxique : https://t.co/NXeSDu6Rbx

RT @akakehasi1: ⚠️HCQ para #lúpus e outras doenças reumáticas; Uso prolongado, melhora sintomas e previne novas manifestações; Uso isolado…

⚠️HCQ para #lúpus e outras doenças reumáticas; Uso prolongado, melhora sintomas e previne novas manifestações; Uso isolado ou com outras medicações; Dose por peso; Exame oftalmológico mais espaçado se a avaliação inicial for normal. https://t.co/xtT9kyie6H

RT @COVID_Evidence: PubMed: Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumat…

RT @COVID_Evidence: PubMed: Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumat…

PubMed: Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases: Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in… https://t.co/Ajap06bTcD #covid19 #

Want to learn about hydroxychloroquine from who knows ?! We Brazilian rheumatologists have “the hand”, as we speak here, to manage it! Don't miss this beautiful review! https://t.co/bEhrnHAldB https://t.co/2XqjoATNSK

A cloroquina e a hidroxicloroquina, utilizadas há anos no tratamento de doenças reumáticas, são hoje motivo de debate devido à pandemia de COVID-19. Neste artigo, os autores revisam a ação das substâncias em pacientes com doenças reumáticas inflamatórias.